refractory hematologic cancer
refractory hematologic cancer
Explore linked clinical trials. Standard reference: MONDO:00041114 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, refractory hematologic cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT03328078 | |
| Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning | Death, Hemic and Lymphatic Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, refractory hematologic cancer | Recruiting | Not applicable | 2026-08-17 | NCT04515810 | |
| Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, refractory hematologic cancer | Recruiting | Not stated | 2026-06-17 | NCT05713214 | |
| International Leukemia Target Board | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, neoplasm, refractory hematologic cancer | Recruiting | Not stated | 2026-01-09 | NCT05270096 |